H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.01 CNY -4.3% Market Closed
Market Cap: 19.8B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hubei Biocause Pharmaceutical Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Long-Term Investments
ÂĄ209.3B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
76%
China Life Insurance Co Ltd
SSE:601628
Long-Term Investments
ÂĄ5.5T
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
16%
Ping An Insurance Group Co of China Ltd
SSE:601318
Long-Term Investments
ÂĄ10.3T
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
14%
New China Life Insurance Company Ltd
SSE:601336
Long-Term Investments
ÂĄ1.1T
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
11%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Long-Term Investments
ÂĄ467.3B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
19.8B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Intrinsic Value
4.79 CNY
Undervaluation 16%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Long-Term Investments?
Long-Term Investments
209.3B CNY

Based on the financial report for Jun 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Long-Term Investments amounts to 209.3B CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
76%

Over the last year, the Long-Term Investments growth was -3%. The average annual Long-Term Investments growth rates for Hubei Biocause Pharmaceutical Co Ltd have been 6% over the past three years , 9% over the past five years , and 76% over the past ten years .

Back to Top